A proposed framework for differences in the mechanisms of APS and CAPS. In APS, a complement-amplifying trigger induces thrombosis in the presence of aPL antibodies such as the lupus anticoagulant, anticardiolipin, or β2GP-I antibodies. The presence of an underlying germline mutation in complement regulatory genes may increase the risk of developing CAPS, a more severe subtype.